Đang chuẩn bị liên kết để tải về tài liệu:
báo cáo hóa học:" The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program"

Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học đề tài : The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program | JOURNAL OF TRANSLATIONAL MEDICINE Society for Immunotherapy of Cancer formerly the International Society for Biological Therapy of Cancer Program Summary October 1 2010 - Washington D.c. Primer on Tumor Immunology and Biological Therapy of Cancer Interaction Innovation Integration Exchange Translation Leadership Guiding cancer immunotherapy from bench to bedside The iSBTc SITC primer on tumor immunology and biological therapy of cancer a summary of the 2010 program Balwit et al. Balwit et al. Journal of Translational Medicine 2011 9 18 http www.translational-medicine.com content 9 1 18 31 January 2011 2 BioMed Central Balwit et al. Journal of Translational Medicine 2011 9 18 http www.translational-medicine.eom content 9 1 18 REVIEW TRANSLATIONAL MEDICINE Open Access The iSBTc SITC primer on tumor immunology and biological therapy of cancer a summary of the 2010 program 12 3 14 James M Balwit Patrick Hwu Walter J Urba Francesco M Marincola 1 Abstract The Society for Immunotherapy of Cancer SITC formerly the International Society for Biological Therapy of Cancer iSBTc aims to improve cancer patient outcomes by advancing the science development and application of biological therapy and immunotherapy. The society and its educational programs have become premier destinations for interaction and innovation in the cancer biologics community. For over a decade the society has offered the Primer on Tumor Immunology and Biological Therapy of Cancer in conjunction with its Annual Scientific Meeting. This report summarizes the 2010 Primer that took place October 1 2010 in Washington D.C. as part of the educational offerings associated with the society s 25th anniversary. The target audience was basic and clinical investigators from academia industry and regulatory agencies and included clinicians post-doctoral fellows students and allied health professionals. Attendees were provided a review of basic immunology and educated on the current status and most recent advances in .